Please login to the form below

Not currently logged in
Email:
Password:

Kiadis Pharma appoints Vincent Brichard to supervisory board

Dr Brichard has over 25 years of experience in oncology and immunology

edit-Kiadis-Vincent-BrichardClinical stage biopharma firm Kiadis Pharma has named Dr Vincent Brichard as an independent member of its supervisory board.

Kiadis has a focus on research, development and commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders, including its lead product Atir.

Commenting on his appointment, Brichard said: “With my background in oncology and immunology, my work has been focused since 1986 on the appealing project of educating our natural defenses – those that protect us from infectious diseases – to recognise and kill cancer cells. 

“Atir achieved some extremely compelling clinical data and the phase II study interim analysis in December demonstrated the drug's true potential as an adjunctive life-saving therapy for blood cancer patients. I am looking forward to joining the board and working with the team to develop Atir to its full potential.

Brichard has more than 25 years of experience in the fields of oncology and immunology, including an almost 15 year stint as GlaxoSmithKline where he served as senior VP and held responsibility for the immunotherapies business unit.

Manfred Rüdiger, CEO of Kiadis, added: “We are very pleased to have attracted someone of Dr Brichard's calibre to the board. His strong background and successful career in oncology and immunology will complement the company's already strong team and network. We look forward to benefiting from his counsel.”

20th May 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics